Fig. 1From: A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesisMRONJ risk profile of patients with metabolic bone fragility receiving Antiresorptive medications (BMAs)Back to article page